Mitsubishi UFJ Asset Management Co. Ltd. Acquires 143,861 Shares of Kenvue Inc. (NYSE:KVUE)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Kenvue Inc. (NYSE:KVUE) by 4.2% during the 4th quarter, HoldingsChannel reports. The firm owned 3,609,212 shares of the company’s stock after purchasing an additional 143,861 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Kenvue were worth $76,515,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Grove Bank & Trust increased its position in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the fourth quarter worth $29,000. SRS Capital Advisors Inc. lifted its stake in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC boosted its holdings in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $23.52 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $22.27 and a 200-day moving average price of $22.46. The firm has a market cap of $44.95 billion, a PE ratio of 44.38, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on KVUE shares. Barclays increased their target price on Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Thursday. Evercore ISI started coverage on shares of Kenvue in a report on Monday. They issued an “in-line” rating and a $25.00 price objective for the company. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. UBS Group dropped their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Finally, Piper Sandler boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.